IL1F10 and prostate carcinoma: In the univariate analysis, IL-38 expression (HR 5.57; 95%CI 1.26-24.69; p=0.024), level of PSA (HR 1.98; 95%CI 1.04-3.77; p=0.038), T staging (HR 5.13; 95%CI 1.63-16.13; p=0.005), TNM staging (HR 2.56; 95%CI 1.45-4.54; p=0.001), and prognostic staging (HR 1.92;95%CI 1.03-3.5; p=0.041 emerged as important factors affecting the survival of prostate cancer patients.